Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...
A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback